Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC trial of NFL-102 for tobacco and nicotine cessation
2026-527266-77-00Phase 2Authorised
- Sponsor
- NFL Biosciences
- Start
- Oct 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of NFL-102 in nicotine dependence (2 arms), sponsored by NFL Biosciences. Primary endpoints: Safety and tolerability by dose level and 4-week continuous abstinence. Planned start Oct 2026; status: authorised.
02
Drugs
NFL-102
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2026-527266-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527266-77-00.